Abstract
Background Preeclampsia, a pregnancy complication characterized by hypertension after 20 gestational weeks, is a major cause of maternal and neonatal morbidity and mortality. The mechanisms leading to preeclampsia are unclear; however, there is evidence that preeclampsia is highly heritable. We evaluated the association of polygenic risk scores (PRS) for blood pressure traits and preeclampsia to assess whether there is shared genetic architecture.
Methods Participants were obtained from Vanderbilt University’s BioVU, the Electronic Medical Records and Genomics network, and the Penn Medicine Biobank. Non-Hispanic Black and White females of reproductive age with indications of pregnancy and genotype information were included. Preeclampsia was defined by ICD codes. Summary statistics for diastolic blood pressure (DBP), systolic blood pressure (SBP), and pulse pressure (PP) PRS were obtained from Giri et al 2019. Associations between preeclampsia and each PRS were evaluated separately by race and study population before evidence was meta-analyzed. Prediction models were developed and evaluated using 10-fold cross validation.
Results In the 3,504 Black and 5,009 White individuals included, the rate of preeclampsia was 15.49%. The DBP and SBP PRSs were associated with preeclampsia in Whites but not Blacks. The PP PRS was significantly associated with preeclampsia in Blacks and Whites. In trans-ancestry meta-analysis, all PRSs were associated with preeclampsia (ORDBP=1.10, 95% CI=1.02-1.17, p=7.68×10−3; ORSBP=1.16, 95% CI=1.09-1.23, p=2.23×10−6; ORPP=1.14, 95% CI=1.07-1.27, p=9.86×10−5). However, addition of PRSs to clinical prediction models did not improve predictive performance.
Conclusions Genetic factors contributing to blood pressure regulation in the general population also predispose to preeclampsia.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Drs. Elizabeth A. Jasper and Jacklyn N. Hellwege are supported by the NIH Building Interdisciplinary Research Career's in Women's Health career development program (K12HD043483 PIs: K.E. Hartmann, A.S. Major, and D.R. Velez Edwards). Dr. Jasper was also supported by a National Human Genome Research Institute award for the Vanderbilt Genomic Medicine Training Program (T32HG008341 PIs: J.F. Peterson, N. Cox, and D.M. Roden). Joseph H. Breeyear was supported by Vanderbilt University Medical Center's Clinical and Translational Award training program (TL1-TR002244 PI: K.E. Hartmann). Iftikhar J. Kullo is funded by grants HG06379 and HG11710 from the National Human Genome Research Institute and K24HL137010 from the National Heart Lung and Blood Institute. BioVU The dataset(s) used for the analyses described were obtained from Vanderbilt University Medical Center's BioVU which is supported by numerous sources: institutional funding, private agencies, and federal grants. These include the NIH funded Shared Instrumentation Grant S10RR025141; and CTSA grants UL1TR002243, UL1TR000445, and UL1RR024975. Genomic data are also supported by investigator-led projects that include U01HG004798, R01NS032830, RC2GM092618, P50GM115305, U01HG006378, U19HL065962, R01HD074711; and additional funding sources listed at https://victr.vumc.org/biovu-funding/. eMERGE Network (Phase III) This phase of the eMERGE Network was initiated and funded by the NHGRI through the following grants: U01HG008657 (Group Health Cooperative/University of Washington); U01HG008685 (Brigham and Women's Hospital); U01HG008672 (Vanderbilt University Medical Center); U01HG008666 (Cincinnati Children's Hospital Medical Center); U01HG006379 (Mayo Clinic); U01HG008679 (Geisinger Clinic); U01HG008680 (Columbia University Health Sciences); U01HG008684 (Children's Hospital of Philadelphia); U01HG008673 (Northwestern University); U01HG008701 (Vanderbilt University Medical Center serving as the Coordinating Center); U01HG008676 (Partners Healthcare/Broad Institute); U01HG008664 (Baylor College of Medicine); and U54MD007593 (Meharry Medical College). eMERGE Network (Phase IV) This phase of the eMERGE Network was initiated and funded by the NHGRI through the following grants: U01HG011172 (Cincinnati Children's Hospital Medical Center); U01HG011175 (Children's Hospital of Philadelphia); U01HG008680 (Columbia University); U01HG011176 (Icahn School of Medicine at Mount Sinai); U01HG008685 (Mass General Brigham); U01HG006379 (Mayo Clinic); U01HG011169 (Northwestern University); U01HG011167 (University of Alabama at Birmingham); U01HG008657 (University of Washington Medical Center); U01HG011181 (Vanderbilt University Medical Center); U01HG011166 (Vanderbilt University Medical Center serving as the Coordinating Center).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The institutional review board of Vanderbilt University Medical Center, Nashville, TN, approved this study (IRB #210756).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos